120例华法林钠抗凝治疗患者CYP2C9基因多态性的研究  

Genetic polymorphism of CYP2C9 in patients receiving warfarin anticoagulant therapy

作　　者：张延博[1] 葛卫红[2] 印晓星[1] 

机构地区：[1]徐州医学院药学院临床药学教研室,徐州医学硕士研究生221002 [2]南京大学医学院附属鼓楼医院药剂科,南京210008

出　　处：《医学研究生学报》2013年第1期45-48,共4页Journal of Medical Postgraduates

摘　　要：目的细胞色素P450 2C9酶(CYP2C9)是人类肝中一种重要的药物代谢酶。因其具有高度多态性,故在基因编码区和非编码区存在许多单碱基突变,对华法林钠等心血管系统药物的代谢产生较大的差异。对此,文中探讨口服华法林钠抗凝治疗具有CYP2C9 1061A/C(CYP2C9*3)基因多态性中国汉族心血管疾病患者的特点,旨在为华法林钠的临床个体化用药提供理论依据和指导。方法应用PCR与基因测序法,检测120例长期口服华法林钠患者的CYP2C9*3基因多态性。结果 120例口服华法林钠抗凝治疗患者CYP2C9*3基因AA、AC、CC型分别为例111(92.5%)、9例(7.5%)、0例(0.0%),等位基因A和C的频率分别为96.25%和3.75%,样本具有群体代表性(χ2=0.182,P>0.05)。结论中国汉族口服华法林钠抗凝治疗患者中存在CYP2C9*3突变基因,并且等位基因频率与其他种族或人群存在差异。Objective Cytochrome P450 2C9 （CYP2C9） is an important drug-metabolizing enzyme in the human liver. The CYP2C9 gene has a genetic polymorphism called single nucleotide polymorphism in both its coding and non-coding regions. The genetic polymorphism can not only lead to significant differences in the metabolism of wafarin and some important cardiovascular drugs. This article aims to research for the theoretical evidence for individualized administration of warfarin by studying the features of CYP2C9 1061 A/C（ CYP2C9 ＊ 3 ） genetic polymorphism in Chinese Han patients with cardiovascular diseases receiving warfarin anticoagulant. Methods Using polymerase chain reaction and gene sequencing, we detected the CYP2C9 ＊ 3 genetic polymorphism in 120 Chinese Han patients with cardiovascular diseases treated by long-term oral administration of warfarin anticoagulant. Results The frequencies of the CYP2C9 ＊ 3 AA, AC, CC genotypes in the patients were 92.5% （ 111/120）, 7.5% （9/120）, and 0.0%, respectively. The allele frequencies were 96.25% for CYP2C9 ＊ 3 A and 3.75% for C. Conclusion The CYP2C9 ＊ 3 mutant is present in Chinese Han patients receiving warfarin anticoagulant, and there are significant differences in the allele frequencies of CYP2C9 between the Chinese Han and other populations.

关 键 词：华法林钠 抗凝 基因多态性 CYP2C9 

分 类 号：R973.2[医药卫生—药品]